DK0751781T3 - Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme - Google Patents

Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme

Info

Publication number
DK0751781T3
DK0751781T3 DK95906686T DK95906686T DK0751781T3 DK 0751781 T3 DK0751781 T3 DK 0751781T3 DK 95906686 T DK95906686 T DK 95906686T DK 95906686 T DK95906686 T DK 95906686T DK 0751781 T3 DK0751781 T3 DK 0751781T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
medicament
prevention
manufacture
treatment
Prior art date
Application number
DK95906686T
Other languages
English (en)
Inventor
Richard J Armitage
William C Fanslow Iii
Dan L Longo
William J Murphy
Original Assignee
Immunex Corp
Nat Inst Of Health As Represen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22628670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0751781(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp, Nat Inst Of Health As Represen filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0751781T3 publication Critical patent/DK0751781T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95906686T 1993-12-23 1994-12-21 Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme DK0751781T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17266493A 1993-12-23 1993-12-23

Publications (1)

Publication Number Publication Date
DK0751781T3 true DK0751781T3 (da) 2004-08-09

Family

ID=22628670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95906686T DK0751781T3 (da) 1993-12-23 1994-12-21 Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme

Country Status (13)

Country Link
US (1) US5674492A (da)
EP (1) EP0751781B1 (da)
JP (1) JPH09507074A (da)
AT (1) ATE267607T1 (da)
AU (1) AU680102B2 (da)
CA (1) CA2179196A1 (da)
DE (1) DE69433820T2 (da)
DK (1) DK0751781T3 (da)
ES (1) ES2222463T3 (da)
NO (1) NO320354B1 (da)
NZ (1) NZ278740A (da)
PT (1) PT751781E (da)
WO (1) WO1995017202A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997022256A1 (en) * 1995-12-19 1997-06-26 National Jewish Center For Immunology And Respiratory Medicine Method to regulate cd40 signaling
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
KR100632846B1 (ko) * 1997-01-10 2006-10-16 바이오겐 아이덱 엠에이 인코포레이티드 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법
CA2294247C (en) * 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
IL136731A0 (en) * 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
AU2114999A (en) * 1998-01-14 1999-08-02 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis of melanoma
US7338767B1 (en) 1998-01-14 2008-03-04 Dana-Farber Cancer Institute, Inc. Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma
US5965712A (en) * 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
WO2000018888A1 (en) * 1998-09-29 2000-04-06 The Uab Research Foundation Immunomodulation by genetic modification of dendritic cells and b-cells
EP1141240A4 (en) * 1998-12-29 2003-09-10 Univ Vermont USE OF THE CD40 COUPLING TO MODIFY THE USE OF THE T-CELL RECEPTOR
EP1185627A2 (en) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US7172759B2 (en) * 2000-02-01 2007-02-06 Pangenetics Bv Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
DE60116075T4 (de) * 2000-04-25 2007-06-06 Immunex Corp., Thousand Oaks Behandlung von tumoren mit photodynamischer therapie
CN1437478A (zh) * 2000-04-25 2003-08-20 Idec药物公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002060485A2 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
JP4765039B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｄ４０抗原を発現する癌に対する治療方法。
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
US20070098717A1 (en) * 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
CN101325970B (zh) 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
CN104357469B (zh) * 2006-05-03 2018-10-26 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其用途
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
BRPI0820707A2 (pt) 2007-11-07 2015-06-16 Genentech Inc Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
KR101787768B1 (ko) 2009-04-18 2017-10-18 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
CN110066335B (zh) 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP3303395B1 (en) 2015-05-29 2019-12-11 AbbVie Inc. Anti-cd40 antibodies and uses thereof
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
US10829522B2 (en) * 2016-04-27 2020-11-10 Osaka University Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP4284512A1 (en) 2021-01-28 2023-12-06 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2312667C (en) * 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment

Also Published As

Publication number Publication date
AU1516895A (en) 1995-07-10
WO1995017202A1 (en) 1995-06-29
EP0751781A1 (en) 1997-01-08
PT751781E (pt) 2004-09-30
CA2179196A1 (en) 1995-06-29
AU680102B2 (en) 1997-07-17
JPH09507074A (ja) 1997-07-15
NO320354B1 (no) 2005-11-28
EP0751781B1 (en) 2004-05-26
NO962526L (no) 1996-08-23
DE69433820D1 (de) 2004-07-01
NO962526D0 (no) 1996-06-14
US5674492A (en) 1997-10-07
EP0751781A4 (en) 1999-09-22
DE69433820T2 (de) 2005-06-23
ES2222463T3 (es) 2005-02-01
NZ278740A (en) 1998-05-27
ATE267607T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
RU99109594A (ru) Способы и композиции для иммуномодуляции
NO993847L (no) FremgangsmÕter og preparater for behandling av allergisk astma og andre sykdommer ved anvendelse av deskarboetoksyloratadin
DK1003546T3 (da) Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
DE68925226T2 (de) Monoklonale Antikörper
HUP0105490A2 (hu) Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
DE69132682D1 (de) Zellwachstumsinhibitoren
DE60037402D1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
DK1019066T3 (da) Fremgangsmåder og præparater til forebyggelse og behandling af halsbrand
UA42351A (uk) Спосіб лікування туберкульозу
BR9609868A (pt) Conjugado sintético de uma proteína e uma pluralidade de epítopos para uso em medicina processos para evitar a rejeição de um xenoenxerto ou pelo menos reduzir a extensão ou taxa de rejeição para tratar uma doença e sangue removido de um doador de sangue aparelho sangue composição farmaceuticamente aceitável e uso de um conjugado
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.